Comparative Pharmacology
Head-to-head clinical analysis: TIMENTIN IN PLASTIC CONTAINER versus VIBATIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIMENTIN IN PLASTIC CONTAINER versus VIBATIV.
TIMENTIN IN PLASTIC CONTAINER vs VIBATIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Timentin is a combination of ticarcillin, a penicillin-class beta-lactam antibiotic, and clavulanate, a beta-lactamase inhibitor. Ticarcillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while clavulanate irreversibly inhibits beta-lactamases, preventing degradation of ticarcillin.
Lipoglycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Also disrupts membrane potential and increases membrane permeability.
3.1 g (ticarcillin 3 g + clavulanate 0.1 g) IV every 4 to 6 hours; maximum 18 g per day.
10 mg/kg intravenously once every 24 hours, infused over 60 minutes for 7 to 14 days.
None Documented
None Documented
Ticarcillin: ~1.2 hours; Clavulanate: ~1.0 hours. Prolonged in renal impairment (ticarcillin up to 15 hours in ESRD).
Terminal elimination half-life is approximately 177 hours (7.4 days), supporting once-daily dosing.
Renal: ~70-80% of ticarcillin and ~60-70% of clavulanate excreted unchanged in urine within 6 hours. Biliary/fecal: Minor (<5%).
Primarily renal excretion as unchanged drug (approximately 93% of dose recovered in urine; <5% in feces).
Category C
Category C
Antibiotic
Antibiotic